Inventor

Barton F. Haynes

Inventor

Durham, NC, US

Overview

1991–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 71 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes25%

C07KPeptides24%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%

C12NMicroorganisms or enzymes19%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%

Y02ATechnologies for adaptation to climate change3%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

A01KAnimal husbandry1%

C07HSugars1%

G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology1%

PatentTitleYear

11,077,130Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies2021 11,071,783HIV-1 neutralizing antibodies and uses thereof2021 11,053,285Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use2021 10,968,255Compositions comprising HIV envelopes to induce CH235 lineage antibodies2021 10,946,090Consensus/ancestral immunogens2021 10,906,941Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage2021 10,865,238Complement factor H antibodies2020 10,849,970Antibody evolution immunogens2020 10,835,599Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol2020 10,730,947Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof2020 10,717,778Bispecific molecules comprising an HIV-1 envelope targeting arm2020 10,626,168B cell lineage based immunogen design with humanized animals2020 10,588,960Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies2020 10,561,725Method of inducing the production of protective anti-HIV-1 antibodies2020 10,450,368HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)2019 10,344,077HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)2019 10,322,141Compositions comprising CH848 envelopes and uses thereof2019 10,286,057Cyclic HIV-1 Env V3 glycopeptide immunogens2019 10,273,291Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing2019 10,232,034Compositions comprising CH505 envelopes, and trimers2019 10,183,988Anti-Complement factor H antibodies2019 10,149,902Swarm immunization with envelopes from CH5052018 10,092,638GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus2018 10,076,567MPER-liposome conjugates and uses thereof2018 10,040,826Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens2018 10,004,800Antibody evolution immunogens2018 9,988,424Immunogens comprising human immunodeficiency virus V1/V2 polypeptides2018 9,963,501B cell lineage based immunogen design with humanized animals2018 9,908,938'Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof'2018 9,855,329'Mosaic HIV envelope immunogenic polypeptides'2018 9,844,589Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses2017 9,844,590Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens2017 9,821,053'Human Immunodeficiency Virus type 1 group M consensus and mosaic envelope glycoproteins'2017 9,718,873'Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin'2017 9,717,789'Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies'2017 9,492,532'Nucleic acids encoding mosaic HIV-1 gag proteins'2016 9,402,917'Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions'2016 9,402,893'Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies'2016 9,044,445'Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens'2015 9,011,875'Human immunodeficiency virus type 1 clade M mosaic gag polypeptides'2015 9,011,873'Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens'2015 8,956,627'Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates'2015 8,926,995'Adjuvant'2015 8,119,140'Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins'2012 8,071,107'Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins'2011 8,048,431'Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain'2011 7,998,471'Mycobacteria expressing HIV-1 and malaria antigens'2011 7,951,377'Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens'2011 7,195,768'Polyvalent immunogen'2007 7,172,761'Polyvalent immunogen'2007 7,153,509'Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope'2006 7,101,552'Immunogen comprising an HIV envelope protein, a ligand and H2 peptide'2006 7,078,039'Immunogenic composition'2006 7,070,787'Method of inducing the production of antibodies to HIV'2006 7,052,699'Immunogenic composition'2006 7,041,294'Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects'2006 7,033,593'Immunogen comprising an HIV envelope protein, a ligand and H2 peptide'2006 6,982,086'Human immunodeficiency virus immunogenic composition'2006 6,544,747'Assay system'2003 6,432,405'Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies'2002 6,270,758'Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects'2001 6,091,000'SCID mouse engrafted with human synovium tissue'2000 5,998,172'Anti-CD6 ligand antibodies'1999 5,993,819'Synthetic vaccine for protection against human immunodeficiency virus infection'1999 5,968,768'CD6 ligand encoding sequence'1999 5,863,540'Adhesion molecule'1999 5,723,437'CD6 ligand'1998 5,516,632'Synthetic peptides'1996 5,352,576'Method of determining the presence and titers of anti HIV-1 ag27bodies'1994 5,019,387'Production of antibodies to HIV'1991 5,013,548'Production of antibodies to HIV'1991

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1991–2021Patents assigned to UNIV DUKE (64)· patent assignee history

1991–2021Based in Durham, NC, US· patent location history

2006–2015Patents assigned to BETH ISRAEL HOSPITAL (8)· patent assignee history

2011–2021Patents assigned to LOS ALAMOS NAT SECURITY LLC (15)· patent assignee history

2011–2019Patents assigned to HAYNES BARTON F (12)· patent assignee history

2011–2017Patents assigned to HAHN BEATRICE H (6)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV DUKE	64	1991–2021
LOS ALAMOS NAT SECURITY LLC	15	2011–2021
HAYNES BARTON Fself	12	2011–2019
BETH ISRAEL HOSPITAL	8	2006–2015
HAHN BEATRICE H	6	2011–2017

Locations

Location	Patents	Span
Durham, NC, US	71	1991–2021